Erika von Euw
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 4
- HER2/EGFR in Cancer Research 4
- Cancer-related Molecular Pathways 4
- Immunology top 10%
- Immunotherapy and Immune Responses 5
- T-cell and B-cell Immunology 4
- Cancer Research top 10%
- Molecular Biology top 10%
- Melanoma and MAPK Pathways 6
- PI3K/AKT/mTOR signaling in cancer 5
- Physiology top 10%
-
- Advanced Breast Cancer Therapies 5
- Co-authors
- Antoni RibasNarsis AttarBegonya Comin-AnduixRichard C. KoyaDennis J. SlamonBartosz ChmielowskiRoger S. LoDeliang Guo
- Cited by
- OncologyImmunologyCancer Research
- Journals
- Cancer Research (7 papers)Journal of Translational Medicine (3 papers)Clinical Cancer Research (2 papers)
- Partner nations
- United StatesArgentinaDenmark
In The Last Decade
Erika von Euw
30 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 85
- Oncology 757
- Immunology 353
- Cancer Research 209
- Molecular Biology 893
- Physiology 42
Countries citing papers authored by Erika von Euw
This map shows the geographic impact of Erika von Euw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika von Euw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika von Euw more than expected).
Fields of papers citing papers by Erika von Euw
This network shows the impact of papers produced by Erika von Euw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika von Euw. The network helps show where Erika von Euw may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Erika von Euw, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 3 | |
| 2 | 2020 | 1 | |
| 3 | 2020 | 17 | |
| 4 | 2018 | 6 | |
| 5 | 2018 | 80 | |
| 6 | 2017 | 1 | |
| 7 | 2015 | 3 | |
| 8 | 2014 | 93 | |
| 9 | 2014 | 93 | |
| 10 | 2013 | 43 | |
| 11 | PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. | 2013 | 88 |
| 12 | 2013 | 40 | |
| 13 | 2012 | 61 | |
| 14 | 2011 | 78 | |
| 15 | 2011 | 183 | |
| 16 | 2010 | 23 | |
| 17 | 2010 | 39 | |
| 18 | 2010 | 171 | |
| 19 | 2009 | 135 | |
| 20 | 2008 | 100 |
About Erika von Euw
Erika von Euw is a scholar working on Oncology, Immunology and Hematology, having authored 30 papers that have together received 1.6k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (6 papers), Advanced Breast Cancer Therapies (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Immunotherapy and Immune Responses (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), HER2/EGFR in Cancer Research (4 papers), Cancer-related Molecular Pathways (4 papers) and T-cell and B-cell Immunology (4 papers). The work is most often cited by research in Oncology (757 citations), Immunology (353 citations) and Cancer Research (209 citations). Erika von Euw has collaborated with scholars based in United States, Argentina and Denmark. Frequent co-authors include Antoni Ribas, Narsis Attar, Begonya Comin-Anduix, Richard C. Koya, Dennis J. Slamon, Bartosz Chmielowski, Roger S. Lo, Deliang Guo, Paul S. Mischel and Charles Ng. Their work appears in journals such as Cancer Research, Journal of Translational Medicine, Clinical Cancer Research, International Journal of Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.